275

    524804

    AUROPHARMA

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    AUROBINDO PHARMA LTD Share Price Today

    AUROBINDO PHARMA LTD is currently trading at ₹1547.5, down by ₹7.69 from the previous close. The stock touched an intraday high of ₹1585.30 and a low of ₹1538.10 during the latest trading session. Over the past one year, AUROBINDO PHARMA LTD has delivered a return of 38.83%, while the stock has gained 6.91% in the last one month.

    AUROBINDO PHARMA LTD performance

    Today’s low Today’s high
    ₹ 1538.10 ₹ 1585.30
    ₹ 1547.10
    52 week low 52 week high
    ₹ 1016.10 ₹ 1585.30
    ₹ 1547.10
    Open Price ₹ 1555.20
    Prev. Close ₹ 1555.20
    Volume (Shares) 3656239.00
    Total traded value ₹ 56565.67
    Upper Circuit ₹ 1710.70
    Lower Circuit ₹ 1399.70
    info

    Investment Returns

    Over 1 Month 6.91% Over 3 Months 18.91% Over 6 Months 28.93% Over 1 Year 38.83%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    AUROBINDO PHARMA LTD fundamentals


    • Market cap (Cr) 89,896.50
    • P/E Ratio (TTM) 37.40
    • Beta 0.47
    • Book Value / share 391.14
    • Return on equity 8.68%
    • EPS (TTM) 41.81
    • Dividend yield 0.26%
    • Net profit/quarter (Cr) 692.23
    info icon alternate text
    • Market cap (Cr) 89,838.40
    • P/E Ratio (TTM) 37.40
    • Beta 0.41
    • Book Value / share 391.14
    • Return on equity 8.68%
    • EPS (TTM) 41.81
    • Dividend yield 0.26%
    • Net profit/quarter (Cr) 692.23
    info icon alternate text

    AUROBINDO PHARMA LTD Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 2746.98
    Operating Expense 2124.33
    Net Profit 692.23
    Net Profit Margin (%) 25.19
    Earnings Per Share (EPS) 11.92
    EBITDA 995.51
    Effective Tax Rate (%) 21.00
    Particulars DEC 2025 (Values in Cr)
    Revenue 2726.38
    Operating Expense 2078.15
    Net Profit 582.07
    Net Profit Margin (%) 21.34
    Earnings Per Share (EPS) 10.02
    EBITDA 902.24
    Effective Tax Rate (%) 25.55
    Particulars SEP 2025 (Values in Cr)
    Revenue 2759.89
    Operating Expense 2193.96
    Net Profit 581.37
    Net Profit Margin (%) 21.06
    Earnings Per Share (EPS) 10.10
    EBITDA 884.22
    Effective Tax Rate (%) 23.02
    Particulars JUN 2025 (Values in Cr)
    Revenue 2822.14
    Operating Expense 2181.85
    Net Profit 559.13
    Net Profit Margin (%) 19.81
    Earnings Per Share (EPS) 9.63
    EBITDA 880.11
    Effective Tax Rate (%) 25.45
    Particulars MAR 2025 (Values in Cr)
    Revenue 2721.43
    Operating Expense 2290.45
    Net Profit 408.17
    Net Profit Margin (%) 14.99
    Earnings Per Share (EPS) 7.03
    EBITDA 710.49
    Effective Tax Rate (%) 26.52
    Particulars MAR 2026 (Values in Cr)
    Revenue 11055.39
    Operating Expense 8578.28
    Net Profit 2414.80
    Net Profit Margin (%) 21.84
    Earnings Per Share (EPS) 41.58
    EBITDA 3662.09
    Effective Tax Rate (%) 23.66
    Particulars MAR 2025 (Values in Cr)
    Revenue 10788.09
    Operating Expense 8902.97
    Net Profit 1746.79
    Net Profit Margin (%) 16.19
    Earnings Per Share (EPS) 29.97
    EBITDA 2885.68
    Effective Tax Rate (%) 25.93
    Particulars MAR 2024 (Values in Cr)
    Revenue 10542.21
    Operating Expense 8858.78
    Net Profit 1954.14
    Net Profit Margin (%) 18.53
    Earnings Per Share (EPS) 33.35
    EBITDA 2840.10
    Effective Tax Rate (%) 20.92
    Particulars MAR 2023 (Values in Cr)
    Revenue 8371.54
    Operating Expense 7269.93
    Net Profit 1227.11
    Net Profit Margin (%) 14.65
    Earnings Per Share (EPS) 21.00
    EBITDA 1948.83
    Effective Tax Rate (%) 23.83
    Particulars MAR 2022 (Values in Cr)
    Revenue 11250.07
    Operating Expense 10245.94
    Net Profit 1454.71
    Net Profit Margin (%) 12.93
    Earnings Per Share (EPS) 24.83
    EBITDA 2069.68
    Effective Tax Rate (%) 11.16
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 562.21
    ROE % 11.15
    ROCE % 14.16
    Total Debt to Total Equity 0.24
    EBITDA Margin 22.61
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 509.35
    ROE % 11.18
    ROCE % 13.51
    Total Debt to Total Equity 0.21
    EBITDA Margin 21.35
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 458.10
    ROE % 7.50
    ROCE % 9.18
    Total Debt to Total Equity 0.16
    EBITDA Margin 16.08
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 419.46
    ROE % 11.38
    ROCE % 12.41
    Total Debt to Total Equity 0.18
    EBITDA Margin 19.39
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 374.29
    ROE % 17.59
    ROCE % 18.29
    Total Debt to Total Equity 0.29
    EBITDA Margin 22.84
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 353.55
    ROE % 8.68
    ROCE % 10.82
    Total Debt to Total Equity 0.19
    EBITDA Margin 26.39
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 336.62
    ROE % 10.35
    ROCE % 11.74
    Total Debt to Total Equity 0.19
    EBITDA Margin 27.19
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 307.80
    ROE % 6.98
    ROCE % 8.18
    Total Debt to Total Equity 0.17
    EBITDA Margin 22.87
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 292.15
    ROE % 8.81
    ROCE % 8.49
    Total Debt to Total Equity 0.18
    EBITDA Margin 18.34
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 271.80
    ROE % 21.49
    ROCE % 22.95
    Total Debt to Total Equity 0.27
    EBITDA Margin 29.76
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 8235.49
    Total Assets 49784.97
    Total Liabilities 49784.97
    Total Equity 32646.93
    Share Outstanding 58
    Price to Book Ratio 3.28
    Return on Assets (%) 7.00
    Return on Capital (%) 8.59
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 6278.30
    Total Assets 45071.51
    Total Liabilities 45071.51
    Total Equity 29850.80
    Share Outstanding 58
    Price to Book Ratio 3.24
    Return on Assets (%) 7.03
    Return on Capital (%) 8.77
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 6084.20
    Total Assets 39889.99
    Total Liabilities 39889.99
    Total Equity 26851.85
    Share Outstanding 58
    Price to Book Ratio 1.68
    Return on Assets (%) 4.83
    Return on Capital (%) 6.08
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 4190.01
    Total Assets 33921.72
    Total Liabilities 33921.72
    Total Equity 24574.05
    Share Outstanding 58
    Price to Book Ratio 2.29
    Return on Assets (%) 7.80
    Return on Capital (%) 9.83
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 5474.28
    Total Assets 33853.99
    Total Liabilities 33853.99
    Total Equity 21928.99
    Share Outstanding 58
    Price to Book Ratio 3.24
    Return on Assets (%) 15.75
    Return on Capital (%) 19.83
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 298.36
    Total Assets 27513.06
    Total Liabilities 27513.06
    Total Equity 20534.11
    Share Outstanding 58
    Price to Book Ratio 3.28
    Return on Assets (%) 6.34
    Return on Capital (%) 6.94
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 94.34
    Total Assets 25153.98
    Total Liabilities 25153.98
    Total Equity 19722.82
    Share Outstanding 58
    Price to Book Ratio 3.24
    Return on Assets (%) 7.76
    Return on Capital (%) 8.67
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 373.41
    Total Assets 25058.81
    Total Liabilities 25058.81
    Total Equity 18034.03
    Share Outstanding 58
    Price to Book Ratio 1.68
    Return on Assets (%) 4.89
    Return on Capital (%) 5.53
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 50.78
    Total Assets 21600.95
    Total Liabilities 21600.95
    Total Equity 17117.34
    Share Outstanding 58
    Price to Book Ratio 2.29
    Return on Assets (%) 6.73
    Return on Capital (%) 7.68
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 386.18
    Total Assets 23188.99
    Total Liabilities 23188.99
    Total Equity 15924.61
    Share Outstanding 58
    Price to Book Ratio 3.24
    Return on Assets (%) 13.42
    Return on Capital (%) 15.66
    Particulars MAR 2025 (Values in Cr)
    Net Income 5066.29
    Cash from Operations 5655.97
    Cash from Investing -1875.80
    Cash from Financing 119.78
    Net change in Cash 2168.60
    Free Cash Flow 7623.83
    Particulars MAR 2024 (Values in Cr)
    Net Income 4379.99
    Cash from Operations 4201.16
    Cash from Investing -4255.95
    Cash from Financing 800.42
    Net change in Cash -1021.01
    Free Cash Flow 6981.49
    Particulars MAR 2023 (Values in Cr)
    Net Income 2612.50
    Cash from Operations 3103.99
    Cash from Investing -3977.75
    Cash from Financing 1814.41
    Net change in Cash 223.41
    Free Cash Flow 5507.79
    Particulars MAR 2022 (Values in Cr)
    Net Income 3372.74
    Cash from Operations 6274.67
    Cash from Investing -3211.56
    Cash from Financing -2969.27
    Net change in Cash -1164.35
    Free Cash Flow 8327.58
    Particulars MAR 2021 (Values in Cr)
    Net Income 7343.59
    Cash from Operations 4614.30
    Cash from Investing 598.69
    Cash from Financing -1364.94
    Net change in Cash 2562.80
    Free Cash Flow 6052.24
    Particulars MAR 2025 (Values in Cr)
    Net Income 2358.45
    Cash from Operations 2314.95
    Cash from Investing -2065.90
    Cash from Financing 616.31
    Net change in Cash 196.20
    Free Cash Flow 2561.89
    Particulars MAR 2024 (Values in Cr)
    Net Income 2475.41
    Cash from Operations 2316.98
    Cash from Investing -159.96
    Cash from Financing -1837.03
    Net change in Cash -282.19
    Free Cash Flow 2734.57
    Particulars MAR 2023 (Values in Cr)
    Net Income 1611.23
    Cash from Operations 2116.80
    Cash from Investing -3457.62
    Cash from Financing 1719.48
    Net change in Cash 78.03
    Free Cash Flow 2470.55
    Particulars MAR 2022 (Values in Cr)
    Net Income 1637.48
    Cash from Operations 4418.78
    Cash from Investing -1613.51
    Cash from Financing -2447.54
    Net change in Cash -334.34
    Free Cash Flow 5032.84
    Particulars MAR 2021 (Values in Cr)
    Net Income 4193.01
    Cash from Operations 3621.26
    Cash from Investing -2648.73
    Cash from Financing -27.94
    Net change in Cash 317.74
    Free Cash Flow 4040.16
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 31.51 13.02 1.52 241.47 23.12 38.85
    BLISS GVS PHARMA LTD 492.50 39.98 4.37 5223.27 118.35 495.00
    CIPLA LTD 1440.30 30.57 3.37 116353.96 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 365.50 16.12 2.64 1075.70 256.40 399.00
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 31.51 22.03 4.05 241.47 23.12 38.85
    AMRUTAJAN HEALTH LTD 538.05 24.12 4.20 1555.54 490.00 789.95
    ASTRAZENECA PHARMA INDIA LTD. 8382.65 109.48 24.01 20956.63 7630.00 9850.00
    BLISS GVS PHARMA LTD 492.50 53.13 4.52 5223.27 118.35 495.00

    AUROBINDO PHARMA LTD shareholding pattern

    Holding
    7.07%
    51.81%
    15.23%
    25.86%
    23.65%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    AUROBINDO PHARMA LTD Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    1547.80 -0.47 redarrow
    red-green-graph indicator
    0 Bearish
    16 Bullish
    • 5 Days 1519.90
    • 26 Days 1469.20
    • 10 Days 1495.00
    • 50 Days 1437.30
    • 12 Days 1489.40
    • 100 Days 1372.80
    • 20 Days 1476.20
    • 200 Days 1303.00
    1550.73 PIVOT
    First Support 1536.47 First Resistance 1569.47 Second Support 1517.73 Second Resistance 1583.73 Third Support 1503.47 Third Resistance 1602.47
    RSI 67.06 ADX 25.54 MACD 20.18 Williams % R -5.63 Commodity Channel Index (CCI) 196.95
    Date 2026-06-25 Week 824315.00 Same Day 1255785.00 Month 697955.00
    1 Year 0.48 3 Year 0.65
    Over 1 Month
    6.91% down
    Over 1 Year
    38.83% down
    Over 3 Months
    18.91% down
    Over 3 Years
    29.18% down
    Over 6 Months
    28.93% down
    Over 5 Years
    10.35% down

    AUROBINDO PHARMA LTD Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    08 Aug 2025 4.0 Interim 08 Aug 2025 Equity shares
    20 Feb 2024 1.5 Interim 2 20 Feb 2024 Equity shares
    20 Nov 2023 3.0 Interim 1 20 Nov 2023 Equity shares
    17 Feb 2023 3.0 Interim 1 17 Feb 2023 Equity shares
    06 Jun 2022 4.5 Interim 4 07 Jun 2022 Equity shares
    18 Feb 2022 1.5 Interim 3 21 Feb 2022 Equity shares
    17 Nov 2021 1.5 Interim 2 18 Nov 2021 Equity shares
    27 Aug 2021 1.5 Interim 30 Aug 2021 Equity shares
    22 Feb 2021 1.5 Interim 3 23 Feb 2021 Equity shares
    23 Nov 2020 1.25 Interim 2 24 Nov 2020 Equity shares
    21 Aug 2020 1.25 Interim 25 Aug 2020 Equity shares
    17 Feb 2020 1.75 Interim 2 18 Feb 2020 Equity shares
    21 Nov 2019 1.25 Interim 23 Nov 2019 Equity shares
    15 Feb 2019 1.25 Interim 2 19 Feb 2019 Equity shares
    20 Nov 2018 1.25 Interim 22 Nov 2018 Equity shares
    20 Feb 2018 1.0 Interim 2 21 Feb 2018 Equity shares
    21 Nov 2017 1.5 Interim 22 Nov 2017 Equity shares
    08 Jun 2017 1.25 Interim 2 09 Jun 2017 Equity shares
    24 Nov 2016 1.25 Interim 25 Nov 2016 Equity shares
    09 Jun 2016 0.7 Interim 4 10 Jun 2016 Equity shares
    18 Feb 2016 0.7 Interim 3 22 Feb 2016 Equity shares
    19 Nov 2015 0.6 Interim 2 20 Nov 2015 Equity shares
    21 Aug 2015 0.5 Interim 25 Aug 2015 Equity shares
    08 Jun 2015 1.0 Interim 3 09 Jun 2015 Equity shares
    16 Feb 2015 2.0 Interim 2 18 Feb 2015 Equity shares
    13 Aug 2014 1.5 Interim 19 Aug 2014 Equity shares
    11 Jun 2014 1.75 Interim 2 12 Jun 2014 Equity shares
    19 Nov 2013 1.25 Interim 20 Nov 2013 Equity shares
    30 Jul 2013 0.5 Final 01 Aug 2013 Equity shares
    18 Feb 2013 1.0 Interim 20 Feb 2013 Equity shares
    30 Jul 2012 1.0 Final 01 Aug 2012 Equity shares
    20 Jul 2011 1.0 Final 22 Jul 2011 Equity shares
    11 Nov 2010 5.0 Interim 12 Nov 2010 Equity shares
    13 Sep 2010 2.0 Final 15 Sep 2010 Equity shares
    05 Feb 2010 3.0 Interim 08 Feb 2010 Equity shares
    16 Dec 2009 1.5 Final 18 Dec 2009 Equity shares
    05 Feb 2009 3.0 Interim 06 Feb 2009 Equity shares
    11 Aug 2008 3.25 Final 13 Aug 2008 Equity shares
    14 Sep 2007 2.5 Final 18 Sep 2007 Equity shares
    20 Sep 2005 0.0 Final 22 Sep 2005 Equity shares
    Ex-Date Ex-Bonus Ratio
    21 Jul 2015 20 Jul 2015 1:1
    01 Apr 2000 15 Mar 2000 1:1
    01 Apr 2000 06 Mar 2000 1:1
    19 Nov 1998 26 Oct 1998 1:1
    Ex-Date Old FV NEW FV Record Date
    10 Feb 2011 5.0 1.0 11 Feb 2011
    23 Oct 2003 10.0 5.0 31 Oct 2003
    Dividend date Dividend amount Dividend type Record date Instrument type
    08 Aug 2025 4.0 Interim 08 Aug 2025 Equity shares
    20 Feb 2024 1.5 Interim 2 20 Feb 2024 Equity shares
    20 Nov 2023 3.0 Interim 1 20 Nov 2023 Equity shares
    17 Feb 2023 3.0 Interim 1 17 Feb 2023 Equity shares
    06 Jun 2022 4.5 Interim 4 07 Jun 2022 Equity shares
    18 Feb 2022 1.5 Interim 3 21 Feb 2022 Equity shares
    17 Nov 2021 1.5 Interim 2 18 Nov 2021 Equity shares
    27 Aug 2021 1.5 Interim 30 Aug 2021 Equity shares
    22 Feb 2021 1.5 Interim 3 23 Feb 2021 Equity shares
    23 Nov 2020 1.25 Interim 2 24 Nov 2020 Equity shares
    21 Aug 2020 1.25 Interim 25 Aug 2020 Equity shares
    17 Feb 2020 1.75 Interim 2 18 Feb 2020 Equity shares
    21 Nov 2019 1.25 Interim 23 Nov 2019 Equity shares
    15 Feb 2019 1.25 Interim 2 19 Feb 2019 Equity shares
    20 Nov 2018 1.25 Interim 22 Nov 2018 Equity shares
    20 Feb 2018 1.0 Interim 2 21 Feb 2018 Equity shares
    21 Nov 2017 1.5 Interim 22 Nov 2017 Equity shares
    08 Jun 2017 1.25 Interim 2 09 Jun 2017 Equity shares
    24 Nov 2016 1.25 Interim 25 Nov 2016 Equity shares
    09 Jun 2016 0.7 Interim 4 10 Jun 2016 Equity shares
    18 Feb 2016 0.7 Interim 3 22 Feb 2016 Equity shares
    19 Nov 2015 0.6 Interim 2 20 Nov 2015 Equity shares
    21 Aug 2015 0.5 Interim 25 Aug 2015 Equity shares
    08 Jun 2015 1.0 Interim 3 09 Jun 2015 Equity shares
    16 Feb 2015 2.0 Interim 2 18 Feb 2015 Equity shares
    13 Aug 2014 1.5 Interim 19 Aug 2014 Equity shares
    11 Jun 2014 1.75 Interim 2 12 Jun 2014 Equity shares
    19 Nov 2013 1.25 Interim 20 Nov 2013 Equity shares
    30 Jul 2013 0.5 Final 01 Aug 2013 Equity shares
    18 Feb 2013 1.0 Interim 20 Feb 2013 Equity shares
    30 Jul 2012 1.0 Final 01 Aug 2012 Equity shares
    20 Jul 2011 1.0 Final 22 Jul 2011 Equity shares
    11 Nov 2010 5.0 Interim 12 Nov 2010 Equity shares
    13 Sep 2010 2.0 Final 15 Sep 2010 Equity shares
    05 Feb 2010 3.0 Interim 08 Feb 2010 Equity shares
    16 Dec 2009 1.5 Final 18 Dec 2009 Equity shares
    05 Feb 2009 3.0 Interim 06 Feb 2009 Equity shares
    11 Aug 2008 3.25 Final 13 Aug 2008 Equity shares
    14 Sep 2007 2.5 Final 18 Sep 2007 Equity shares
    20 Sep 2005 0.0 Final 22 Sep 2005 Equity shares
    Ex-Date Ex-Bonus Ratio
    21 Jul 2015 20 Jul 2015 1:1
    01 Apr 2000 15 Mar 2000 1:1
    01 Apr 2000 06 Mar 2000 1:1
    19 Nov 1998 26 Oct 1998 1:1
    Ex-Date Old FV NEW FV Record Date
    10 Feb 2011 5.0 1.0 11 Feb 2011
    23 Oct 2003 10.0 5.0 31 Oct 2003

    Top Gainers

    Top Losers

    Aurobindo Pharma Share Result Highlights

    Aurobindo Pharma reported Q2 revenue of ₹7,796 crore for this financial year, reflecting a YoY growth of 7.99%. Operating profit reached ₹1,566 crore with an OPM of 20%. Profit after tax stood at ₹817 crore, a YoY growth of 9%, despite a sequential dip from Q1 of this year. Over the last decade, compounded sales growth was 14%, and profit growth was 11%. Return on equity, over the same period was 16%.

    Aurobindo Pharma Share Annual Reports

    For FY24, Aurobindo Pharma achieved a 16.68% sales growth, reaching ₹29,002 crore compared to ₹24,859 crore in FY23. Net profit stood at ₹3,169 crore, highlighting moderate recovery despite lower profitability over recent years. EPS for the year was ₹54.15. The company’s 10-year compounded profit growth averaged 11%, but three-year growth remained stagnant at -1%. Return on equity, though stable, declined to 12% last year, reflecting the challenges in maintaining margins in a competitive sector. Aurobindo Pharma’s share price saw an increase of 19% in the last 1-year period.

    Aurobindo Pharma Share Dividend

    Aurobindo Pharma’s dividend payout declined to 8% in FY24, down from 23% in FY23, indicating a shift in financial priorities. The dividend yield for the year stood at a modest 0.37%. While the company’s long-term growth in sales and profits is robust, recent profit stagnation (-1% compounded growth over three years) and declining returns on equity have impacted dividend trends.

    Additional FAQs

    1. Who is the CEO of Aurobindo Pharma Ltd?

    Mr. K. Nithyananda Reddy is the Vice Chairman and Managing Director of Aurobindo Pharma Ltd. He oversees the company’s operations and global pharmaceutical initiatives.

     

    2. When was Aurobindo Pharma Ltd established?

    Aurobindo Pharma Ltd was established in 1986 and has grown into a prominent pharmaceutical company with a significant presence in both domestic and international markets.

     

    3. What factors influence the Aurobindo Pharma Share Price?

    Aurobindo Pharma’s share price is influenced by factors such as regulatory approvals, the launch of new pharmaceutical products, revenue growth, and global market conditions for generics and APIs.

     

    4. Is Aurobindo Pharma Ltd debt free?

    No, Aurobindo Pharma Ltd is not debt free, as it utilises borrowings to support its manufacturing, research, and global expansion efforts.

     

    5. What is the CAGR of Aurobindo Pharma Share?

    The CAGR of Aurobindo Pharma’s share is 8% over 10 years, 22% over 5 years, and 22% over 3 years.

     

    6. How has the Aurobindo Pharma Share Price performed over the past year?

    Over the past year, Aurobindo Pharma’s share price has increased by 19%, reflecting improved business performance and market sentiment toward its pharmaceutical offerings.

     

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Aurobindo Pharma Ltd?

    Answer Field

    Aurobindo Pharma Ltd share price is for NSE ₹ 1,547.50 & for BSE ₹ 1,551.80 as on Jun 29 2026 03:30 PM.

    What is the Market Cap of Aurobindo Pharma Ltd Share?

    Answer Field

    The market cap of Aurobindo Pharma Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jun 29 2026 03:30 PM.

    What is the 52 Week High and Low of Aurobindo Pharma Ltd?

    Answer Field

    The 52 Week High and Low of Aurobindo Pharma Ltd for NSE is ₹ 1,585.30 and ₹ 1,016.10 and for BSE is ₹ 1,585.55 and ₹ 1,017.00.

    What is 1 year return for Aurobindo Pharma Ltd?

    Answer Field

    The 1 year returns on the stock has been 38.83%.

    What is the P/E Ratio of Aurobindo Pharma Ltd Share?

    Answer Field

    As on Jun 29 2026 03:30 PM the price-to-earnings (PE) ratio for Aurobindo Pharma Ltd share is 37.40.

    What is the PB ratio of Aurobindo Pharma Ltd Share?

    Answer Field

    As on Jun 29 2026 03:30 PM, the price-to-book (PB) ratio for Aurobindo Pharma Ltd share is 391.14.

    How to Buy Aurobindo Pharma Ltd Share?

    Answer Field

    You can trade in Aurobindo Pharma Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Aurobindo Pharma Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Aurobindo Pharma Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Aurobindo Pharma Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    Who is the CEO of Aurobindo Pharma Ltd?

    Answer Field

    Mr. K. Nithyananda Reddy is the Vice Chairman and Managing Director of Aurobindo Pharma Ltd. He oversees the company’s operations and global pharmaceutical initiatives.

    When was Aurobindo Pharma Ltd established?

    Answer Field

    Aurobindo Pharma Ltd was established in 1986 and has grown into a prominent pharmaceutical company with a significant presence in both domestic and international markets.

    What factors influence the Aurobindo Pharma Share Price?

    Answer Field

    Aurobindo Pharma’s share price is influenced by factors such as regulatory approvals, the launch of new pharmaceutical products, revenue growth, and global market conditions for generics and APIs.

    Is Aurobindo Pharma Ltd debt free?

    Answer Field

    No, Aurobindo Pharma Ltd is not debt free, as it utilises borrowings to support its manufacturing, research, and global expansion efforts.

    What is the CAGR of Aurobindo Pharma Share?

    Answer Field

    The CAGR of Aurobindo Pharma’s share is 8% over 10 years, 22% over 5 years, and 22% over 3 years.

    How has the Aurobindo Pharma Share Price performed over the past year?

    Answer Field

    Over the past year, Aurobindo Pharma’s share price has increased by 19%, reflecting improved business performance and market sentiment toward its pharmaceutical offerings.

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |